NDC product
Lapatinib
NDC 0480-3237 · Teva Pharmaceuticals, Inc.
Key facts
| Product NDC | 0480-3237 |
|---|---|
| Proprietary name | Lapatinib |
| Nonproprietary name | Lapatinib |
| Substances | LAPATINIB DITOSYLATE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Teva Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA217968 |
| Pharmacologic classes | Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA] |
| Marketing start | Dec 19, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: